Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for hormone-relapsed metastatic prostate cancer:
- Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (2026) NICE technology appraisal guidance 1130
- Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (2024) NICE technology appraisal guidance 951
This page was last updated: